Polprazol Acidcontrol from Polpharma for acid reflux and heartburn. How to use?

Polprazol Acidcontrol is a drug used to treat gastroesophageal reflux and heartburn. The preparation affects the gastrointestinal tract, inhibiting the secretion of hydrochloric acid in the stomach. The drug is available over the counter.

Indications for action of the drug Polprazol Acidcontrol

1. Adults: 10-20 mg once a day for two weeks; if after this period the symptoms improve or symptoms return rapidly after treatment, further investigations should be carried out. Consider using lower doses in people with hepatic impairment.

Polprazol Acidcontrol versus contraindications and warnings

1. Hypersensitivity to any component of the preparation is a contraindication to the use of Polprazol Acidcontrol.
2. Do not use the drug in parallel with atazanavir.
3. Do not use in people under 18 years of age.
4. Before using Polprazol Acidcontrol, the neoplastic process as a possible cause of the symptoms should be excluded (special care should be taken when symptoms include weight loss, frequent vomiting, difficulty swallowing, vomiting blood, tarry stools, jaundice, anemia, peptic ulcer disease).
5. People with liver dysfunction should consult a doctor before using the preparation.
6. Patients with severe hepatic impairment should have their liver enzymes checked regularly.
7. Patients over 45 years of age taking regular indigestion or heartburn medication, who noticed new symptoms or a change in the nature of their existing symptoms, should immediately inform their doctor.
8. The use of Polprazol Acidcontrol (and other antacids) increases the risk of bacterial infections of the gastrointestinal tract.
9. After intravenous administration of the preparation, loss of sight or hearing has been observed; although no such cases have been observed after oral administration.
10. Caution should be exercised in critically ill patients for whom eye and hearing monitoring is recommended.
11. The preparation contains sucrose; patients with hereditary problems associated with fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not use the preparation.
12. 1 capsule contains 0,3265 mg of sodium, which should be taken into account for people on a low-sodium diet.
13. Due to the content of sunset yellow, the preparation may cause allergic reactions.
14. Do not use the preparation in pregnant women without consulting a doctor and medical recommendation. Use during breastfeeding is not recommended due to the lack of data on the safety of its use in this period.
15. People driving motor vehicles should be especially careful as the drug may cause side effects that may impair psychophysical fitness and the ability to drive and operate motor vehicles (dizziness and headache, blurred vision, drowsiness).

1. The following may occur: headache, diarrhea, constipation, abdominal pain, vomiting, flatulence, paresthesia, somnolence, sleep disturbances, balance disorders, rash, itching, hair loss, increased liver enzymes, malaise.
2. Rarely, the following may occur: aggression, depression, hallucinations, visual disturbances (blurred vision, reduced field of vision), hearing impairment, gastrointestinal yeast infection, dry mouth, pancreatitis, joint and muscle pain, hepatitis with or without jaundice, liver failure , encephalopathy (in patients with severe liver failure), gynaecomastia, hypochromic anemia, thrombocytopenia, leukopenia, agranulocytosis, impotence, interstitial nephritis, peripheral edema, decreased sodium concentration in the blood (hyponatraemia), hypersensitivity reactions: urticaria, angioedema, angioedema, , anaphylactic shock, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis.

Interactions of the drug Polprazol Acidcontrol with others

1. The use of the preparation may reduce the absorption of ketoconazole, itraconazole and other drugs.
2. Omeprazole may prolong the elimination time of drugs metabolised by cytochrome P450 (diazepam, thiazolam, flurazepam, phenytoin, warfarin).
3. It is recommended to monitor phenytoin and warfarin concentrations and possibly reduce their doses.
4. The metabolism and elimination time of drugs such as hexobarbital, citalopram, imipramine, clomipramine and also disulfiram may be altered.
5. The preparation inhibits the antiplatelet effect of clopidogrel.
6. Use with clarithromycin increases the plasma levels of both drugs.
7. Omeprazole may increase the blood concentration of the concurrently administered cyclosporin or tacrolimus, reduce the absorption of orally administered vitamin B12, and increase the bioavailability of digoxin.
8. Herbal preparations containing St. John’s wort or other acid-blocking drugs (such as ranitidine, famotidine) should not be used.
9. There were no interactions with antacids. Use with atazanavir is contraindicated.